{"id":"958ce151-fb9f-429a-bc1c-7362af91bbad","modelId":"abadf566-b528-4b44-be3e-418ca078e920","versionId":null,"locationId":"1f672777-9422-4b11-8e4d-4fd9e8209c30","operatorId":null,"ownerId":null,"slug":"asensus-senhance-eu","status":"active","firstSeen":"2017-01-01T12:00:00.000Z","manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.asensus.com/senhance","title":"Senhance surgical system","sourceName":"Asensus Surgical"},{"url":"https://www.fda.gov/medical-devices/medical-device-recalls/asensus-surgical-recalls-senhance-digital-surgical-system-haptic-feedback","title":"Senhance haptic feedback recall","sourceName":"FDA"},{"url":"https://www.globenewswire.com/news-release/2023/11/06/2773902/0/en/Asensus-Surgical-Announces-Klinikum-Idar-Oberstein-Hospital-in-Germany-to-Initiate-Senhance-Surgery-Program.html","title":"Klinikum Idar-Oberstein Germany Senhance Nov 2023","sourceName":"GlobeNewswire / Asensus"},{"url":"https://www.lmu-klinikum.de/the-hospital/locations/future-grosshadern/the-new-hauner/latest-news/senhance-or-system/c00d0cff7782bebc","title":"LMU Munich Senhance pediatric OR system Jan 2023","sourceName":"LMU Klinikum"},{"url":"https://ir.asensus.com/news-releases/news-release-details/asensus-surgical-announces-lkh-universitatsklinikum-graz","title":"LKH Graz Austria Senhance Jul 2024","sourceName":"Asensus IR"},{"url":"https://www.globenewswire.com/news-release/2023/12/20/2799143/0/en/Asensus-Announces-Sale-of-Senhance-Robotic-System-in-Romania.html","title":"Louis Turcanu Hospital Romania Senhance Dec 2023","sourceName":"GlobeNewswire / Asensus"}],"notes":null,"keyFacts":[{"date":"2017-01-01","label":"CE mark","value":"Active for laparoscopic surgery","source":"Asensus regulatory","category":"regulatory"},{"date":"2024-01-01","label":"EU sites","value":"~10+ hospitals (Italy, Germany, France, Spain)","source":"Asensus investor presentations","category":"scale"},{"date":"2021-01-01","label":"Haptic feedback recall","value":"2021 recall of haptic feedback module; corrective action completed","source":"FDA recall database","category":"software_defect"}],"reviewNote":"Verified: Asensus Senhance deployed across Europe 2023-2024. Germany: LMU Klinikum Munich (Jan 2023, pediatric), Klinikum Idar-Oberstein (Nov 2023), University Hospital Tübingen (Dec 2021). Austria: LKH Graz (Jul 2024). Romania: Louis Turcanu Hospital Timișoara (Dec 2023). Honest-absence: no verified Italy deployment in primary sources 2023-2024.","exposureHours":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-06-07T14:06:13.586Z","updatedAt":"2026-06-07T16:09:37.262Z","model":{"id":"abadf566-b528-4b44-be3e-418ca078e920","companyId":"a3a097cb-a5db-4ffd-b421-5eb14335dbcf","modelName":"Senhance","slug":"asensus-senhance","description":"Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.","formFactor":"surgical","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"notes":[{"label":"Verified","value":"Asensus Surgical (formerly TransEnterix; Durham NC; was NYSE American: ASXC) made the Senhance laparoscopic robot, FDA-cleared via 510(k) in Oct 2017 with subsequent clearances/indication expansions. Senhance is a genuinely cleared, commercial (if low-volume) product."},{"label":"Current status: ACQUIRED by Karl Storz (the headline)","value":"Karl Storz acquired 100% of Asensus, closing Aug 22 2024 at $0.35/share (~$95M total, ~67% premium); the stock ceased trading on NYSE American at close (delisted; now a private Karl Storz subsidiary). The canonical big-medtech-acquires-struggling-robotics-startup datapoint: a former public-market name sold for a fraction of its historic enterprise value. maturityStage=commercial (Senhance is cleared + still a product line); company status=acquired; lifecycleState=active (Senhance line continues under Karl Storz)."},{"label":"LUNA = research","value":"The next-gen LUNA (real-time 'clinical intelligence' + cloud ML) was NOT FDA-submitted / NOT cleared / NOT for sale as of the Aug 2024 close. Karl Storz had targeted 2025 FDA - that target is unverified as met. LUNA = research-tier; current status under private-owner Karl Storz is not publicly traceable (cap-flag)."},{"label":"AI-substance + claimed-not-verified","value":"Cleared 'digital surgery' substance = machine-vision/digital-laparoscopy assists (real but incremental, not autonomy); 'Performance-Guided Surgery' framing oversold vs what's cleared. NOT verified: LUNA FDA submission/clearance ever occurring; current Senhance installed-unit count (Karl Storz private); whether Senhance is actively commercialized vs wound down under Karl Storz."}],"products":"Senhance: FDA-cleared multi-port laparoscopic robotic system (initial 510(k) Oct 2017 as TransEnterix; later 3mm instruments, ultrasonic, indication expansions, machine-vision clearance). LUNA: next-gen system (unveiled Feb 2023) with claimed real-time clinical intelligence + cloud ML; NOT FDA-submitted/cleared, NOT for sale.","formFactor":"surgical (multi-port laparoscopic teleoperated robotic system with machine-vision/digital-laparoscopy assists)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.globenewswire.com/news-release/2024/08/22/asensus-surgical-karl-storz-closing","title":"Asensus Surgical: closing of acquisition by Karl Storz ($0.35/sh, ~$95M; delisted; LUNA not cleared)","sourceName":"Asensus (GlobeNewswire)"},{"url":"https://www.massdevice.com/asensus-surgical-karl-storz-acquisition/","title":"Asensus agrees to be acquired by Karl Storz (~$95M, 67% premium)","sourceName":"MassDevice"},{"url":"https://www.urologytimes.com/view/transenterix-senhance-fda-clearance","title":"TransEnterix (Asensus) Senhance US FDA 510(k) clearance (Oct 2017)","sourceName":"Urology Times"},{"url":"https://www.therobotreport.com/karl-storz-closes-acquisition-of-asensus-surgical/","title":"Karl Storz closes acquisition of Asensus Surgical (Aug 2024)","sourceName":"The Robot Report"}],"aliases":["Senhance","Asensus Senhance","TransEnterix Senhance","LUNA"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T20:12:50.702Z","updatedAt":"2026-06-03T20:12:50.702Z","company":{"id":"a3a097cb-a5db-4ffd-b421-5eb14335dbcf","name":"Asensus Surgical","slug":"asensus-surgical","description":"Surgical-robotics company (formerly TransEnterix; Durham NC) of the FDA-cleared Senhance laparoscopic robot and the uncleared LUNA system; acquired by Karl Storz (Aug 2024, ~$95M) and delisted.","status":"acquired by Karl Storz (Aug 2024; ~$95M; delisted)","founded":2006,"hq":"Durham, North Carolina, USA","fundingTotal":null,"type":"both","reviewStatus":"reviewed","sources":[{"url":"https://www.globenewswire.com/news-release/2024/08/22/asensus-surgical-karl-storz-closing","title":"Asensus Surgical: closing of acquisition by Karl Storz ($0.35/sh, ~$95M; delisted; LUNA not cleared)","sourceName":"Asensus (GlobeNewswire)"},{"url":"https://www.massdevice.com/asensus-surgical-karl-storz-acquisition/","title":"Asensus agrees to be acquired by Karl Storz (~$95M, 67% premium)","sourceName":"MassDevice"},{"url":"https://www.urologytimes.com/view/transenterix-senhance-fda-clearance","title":"TransEnterix (Asensus) Senhance US FDA 510(k) clearance (Oct 2017)","sourceName":"Urology Times"},{"url":"https://www.therobotreport.com/karl-storz-closes-acquisition-of-asensus-surgical/","title":"Karl Storz closes acquisition of Asensus Surgical (Aug 2024)","sourceName":"The Robot Report"}],"keyFacts":[{"label":"Product","value":"Senhance laparoscopic robot (FDA 510(k) Oct 2017); LUNA next-gen (uncleared)."},{"label":"Acquisition","value":"Karl Storz, closed Aug 22 2024, $0.35/sh ~$95M; delisted."}],"aliases":["Asensus","TransEnterix","Senhance","Karl Storz"],"collisionRisk":"low","reviewNote":null,"createdAt":"2026-06-03T20:12:49.932Z","updatedAt":"2026-06-03T20:12:49.932Z"}},"version":null,"location":{"id":"1f672777-9422-4b11-8e4d-4fd9e8209c30","name":"European Union","slug":"european-union","kind":"region","parentLocationId":null,"lat":null,"lng":null,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-05-31T13:17:45.465Z","updatedAt":"2026-05-31T13:17:45.465Z"},"operator":null,"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/asensus-senhance-eu","url":"https://registry.deploy.report/deployments/asensus-senhance-eu","name":"Senhance at European Union","identifier":"958ce151-fb9f-429a-bc1c-7362af91bbad","startDate":"2017-01-01T12:00:00.000Z","eventStatus":"https://schema.org/EventScheduled","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/european-union","name":"European Union"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/asensus-surgical","name":"Asensus Surgical"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/asensus-senhance","name":"Senhance"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"commercial","lifecycle_state":"active","architectural_position":{"cohort":"surgical","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":6,"primary_source_types":["primary-company-ir","primary-fda-database"]}}}